Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks
Working with human immune cells in the laboratory, Johns Hopkins researchers report they have identified a critical cellular “off” switch for the inflammatory immune response that contributes to lung-constricting asthma attacks. The switch, they say, is composed of regulatory proteins that control an immune signaling pathway in cells.
“Asthma patients are constantly firing through this pathway because those proteins are stuck in the ‘on’ position, without proper control by other proteins that shut down this reaction,” says Nicola Heller, Ph.D., assistant professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine.
Asthma has been correlated with an overabundance of one type of immune cell called M2 macrophages in the lungs. In a nonasthmatic person, the M2 macrophages activate to clean up inhaled allergens and foreign particles, and then deactivate when the irritant is broken down.
However, in people with asthma, the M2 cells and the chemical signals they emit linger and call in other cells that cause inflammation that can trigger an asthma attack with the classic symptoms of difficulty breathing, wheezing and shortness of breath. Over time, the lung is changed by secretions from the M2 cells, which cause the lung tissue to remodel itself, contributing to irreversible obstruction and poor lung function. “If you prevent these cells from becoming the M2 type, you can potentially stop the continued inflammation and long-term structural changes,” says Heller.
The new research, reported Nov. 25 in the Journal of Biological Chemistry, investigated the role of two proteins, GRB10 and p70S6K, in the control of the signaling pathway that activates M2 cells.
In their previous work, also published in the Journal of Biological Chemistry Sept. 23, Heller’s group found that the inflammatory pathway involving the two proteins begins with interleukin 4 (IL-4), an immune system chemical that passes through a protein named IRS-2 before activating the M2 cells. They found that other proteins that stop the action of IRS-2 were not present in human M2 cells from people with allergies compared to healthy people. This made IRS-2 more active and increased the formation of M2 cells in people with allergies.
In the new study, Heller’s lab delved deeper into the IRS-2 pathway. By analyzing chemical changes of the IRS-2 protein in immortalized cultures of human white blood cells, it determined that IRS-2 appeared in two different forms — “on,” which allows the signal to pass through, and “off,” which stops the signal from activating the cells into M2 macrophages. They began by observing which proteins became active in the presence of IL-4 in human white blood cells and add “stop” signals to IRS-2. The activity of two regulatory proteins, GRB10 and p70S6K, increased after IL-4 exposure compared to the same cells that were not exposed to IL-4.
In further test tube experiments, the researchers treated the immortalized white blood cells with both chemical and genetic blockers, called small interfering RNA (siRNA), designed to render either p70S6K or GRB10 nonfunctional. The researchers saw that decreased GRB10 and p70S6K activity resulted in more of the “on” form of IRS-2, meaning these proteins are responsible for turning off IRS-2 and thereby downstream M2 production.
“This confirmed for us that without properly functioning GRB10 and p70S6K, the cells could not turn off IRS-2 signaling and M2 production,” says Heller.
The research team, Heller says, has already begun experiments to further explore the implications of these results, which include looking at differences in this pathway between cells taken from allergic and healthy individuals, and testing the efficacy of an inhalable drug that mimics the function of GRB1 and p70S6K to shut off the development of M2 macrophages in the lungs of mice. “One of the advantages of working with lung macrophages is that they are one of the first cells that see anything that gets put in an inhaler,” says Heller. “So we hope to modulate their activity in this way.”
These findings also have implications for treatment of cancer and other disorders, such as obesity, in which M2 macrophage cells play a regulatory role in tumor growth and fat deposition.
Learn more: Turning off Asthma Attacks
Receive an email update when we add a new ASTHMA article.
The Latest on: Asthma
via Google News
The Latest on: Asthma
- Asthma is a major cause of frequent absenteeism in school, says Adeyeyeon April 10, 2021 at 9:17 pm
The study detected asthma symptoms amongst more than 10,000 students aged 12 to 14 in 40 secondary schools in Lagos, as part of an international ...
- This Major Mac & Cheese Brand Is Being Sued for Toxins Linked to Asthma and Obesityon April 10, 2021 at 9:58 am
Arguably the best-known macaroni and cheese for decades is being sued for allegedly using toxins shown to harm the health of some children.
- Maternal History of Asthma Drives Risk of Atopic Dermatitis for Their Childrenon April 9, 2021 at 2:02 pm
Children who were born to women with a history of asthma had a 45% increased risk of being diagnosed with atopic dermatitis/eczema up to age 8 years.
- Bless You: Hay fever and asthma affect more people, and earlieron April 9, 2021 at 8:10 am
And for asthma, the proportion has risen from 4 to 12 per cent during the same period. This is shown by a study of 53,000 Danish blood donors published by researchers from Aarhus University in ...
- Asthma Spacers Market to Witness Widespread Expansion During 2021-2025|Says Kenneth Researchon April 8, 2021 at 9:43 pm
The MarketWatch News Department was not involved in the creation of this content. Apr 09, 2021 (AmericaNewsHour) -- Kenneth Research recently added a report on 'Asthma Spacers Market’ in its database ...
- Asthma Therapeutics Market Report 2021-2026 | Industry Size, Future Growth. Companies Share, Structure, Scope and Competitive Outlookon April 8, 2021 at 3:51 am
Apr 08, 2021 (SUPER MARKET RESEARCH via COMTEX) -- According to IMARC Group's latest report, titled "Asthma Therapeutics Market: Global Industry Size, Share, Trends, Growth, Opportunities, Competitive ...
- Improved asthma control during the COVID-19 pandemic: are there lessons to be learnt?on April 7, 2021 at 5:00 pm
While the health impacts of acute COVID-19 pneumonia and long COVID have rightly been the focus of major medical research over the last 12 months, for many patients and healthcare providers an equal ...
- US-Mexico asthma study examines hygiene hypothesis amid pandemicon April 6, 2021 at 8:59 pm
TUCSON, Ariz. -- A cross-border investigation of children's susceptibility to asthma and other childhood illnesses in the United States and Mexico is the focus of a new study led by researchers in the ...
- School-based self-management interventions for asthma among primary school children: a systematic reviewon March 31, 2021 at 5:00 pm
A Cochrane review of school-based asthma interventions (combining all ages) found improved health outcomes. Self-management skills, however, vary according to age. We assessed effectiveness of primary ...
via Bing News